目的:探讨枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)患者肠道菌群失调的干预作用.方法:选择肠道菌群中具有代表性的细菌共8种(肠杆菌、肠球菌、葡萄球菌、双歧杆菌、乳杆菌、拟杆菌、梭菌...目的:探讨枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)患者肠道菌群失调的干预作用.方法:选择肠道菌群中具有代表性的细菌共8种(肠杆菌、肠球菌、葡萄球菌、双歧杆菌、乳杆菌、拟杆菌、梭菌、酵母样真菌)进行培养和计数,检测所有被研究者的血清内毒素、TNF-α、IL-6和ALT的浓度.选择健康正常成人30例作为正常对照组(A组),NASH共60例,随机分为常规治疗组(B组)和观察组(C组)各30例,B组采用常规保肝治疗,C组常规保肝治疗的同时联用枯草杆菌肠球菌二联活菌胶囊治疗,治疗4wk,比较各组治疗前后肠道细菌数量的变化和内毒素、TNF-α、IL-6、ALT的变化,并比较B组和C组治疗后临床症状的缓解情况.结果:与A组比较,治疗前NASH组肠杆菌显著增多(7.28±1.22 vs 6.54±1.08,t=4.83,P<0.01),而双歧杆菌、乳酸杆菌、拟杆菌显著减少(7.13±1.28 vs 8.83±1.24,t=-6.65,P<0.01;6.67±1.21 vs 7.31±1.12,t=-2.16,P<0.05;6.99±1.31 vs 7.82±1.15,t=-2.41,P<0.05);血清中内毒素、IL-6、TNF-的浓度显著增高(168.37EU/L±24.13EU/L vs 110.53EU/L±18.33EU/L,t=11.69,P<0.01;42.62ng/L±12.65ng/L vs 21.58ng/L±8.47ng/L,t=7.71,P<0.01;15.98ng/L±3.19ng/L vs 8.63ng/L±2.49ng/L,t=11.97,P<0.01);C组治疗后与治疗前比较双歧杆菌、乳杆菌、拟杆菌的数量显著增多(P<0.01),肠杆菌的数量显著减少(P<0.05),血清中内毒素、TNF-α、IL-6、ALT的浓度显著降低(P<0.01),C组治疗后临床症状较B组有显著改善.结论:NASH患者存在肠道菌群失调、革兰氏阴性杆菌过度生长,提示肠道微生态失衡可能参与了NASH的发生发展.枯草杆菌肠球菌二联活菌胶囊可明显改善NASH肠道菌群失调,降低血清中内毒素、TNF-α、IL-6、ALT的水平,改善临床症状.展开更多
Bacillus subtilis TA208 was selected as the test strain to optimize the fermentation medium and con- ditions of guanosine producing by single-factor experiments in shake flask. Under the optimum conditions, the produc...Bacillus subtilis TA208 was selected as the test strain to optimize the fermentation medium and con- ditions of guanosine producing by single-factor experiments in shake flask. Under the optimum conditions, the productivity of guanosine was 27.34g/L in 5L auto-fermentor.展开更多
文摘目的:探讨枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)患者肠道菌群失调的干预作用.方法:选择肠道菌群中具有代表性的细菌共8种(肠杆菌、肠球菌、葡萄球菌、双歧杆菌、乳杆菌、拟杆菌、梭菌、酵母样真菌)进行培养和计数,检测所有被研究者的血清内毒素、TNF-α、IL-6和ALT的浓度.选择健康正常成人30例作为正常对照组(A组),NASH共60例,随机分为常规治疗组(B组)和观察组(C组)各30例,B组采用常规保肝治疗,C组常规保肝治疗的同时联用枯草杆菌肠球菌二联活菌胶囊治疗,治疗4wk,比较各组治疗前后肠道细菌数量的变化和内毒素、TNF-α、IL-6、ALT的变化,并比较B组和C组治疗后临床症状的缓解情况.结果:与A组比较,治疗前NASH组肠杆菌显著增多(7.28±1.22 vs 6.54±1.08,t=4.83,P<0.01),而双歧杆菌、乳酸杆菌、拟杆菌显著减少(7.13±1.28 vs 8.83±1.24,t=-6.65,P<0.01;6.67±1.21 vs 7.31±1.12,t=-2.16,P<0.05;6.99±1.31 vs 7.82±1.15,t=-2.41,P<0.05);血清中内毒素、IL-6、TNF-的浓度显著增高(168.37EU/L±24.13EU/L vs 110.53EU/L±18.33EU/L,t=11.69,P<0.01;42.62ng/L±12.65ng/L vs 21.58ng/L±8.47ng/L,t=7.71,P<0.01;15.98ng/L±3.19ng/L vs 8.63ng/L±2.49ng/L,t=11.97,P<0.01);C组治疗后与治疗前比较双歧杆菌、乳杆菌、拟杆菌的数量显著增多(P<0.01),肠杆菌的数量显著减少(P<0.05),血清中内毒素、TNF-α、IL-6、ALT的浓度显著降低(P<0.01),C组治疗后临床症状较B组有显著改善.结论:NASH患者存在肠道菌群失调、革兰氏阴性杆菌过度生长,提示肠道微生态失衡可能参与了NASH的发生发展.枯草杆菌肠球菌二联活菌胶囊可明显改善NASH肠道菌群失调,降低血清中内毒素、TNF-α、IL-6、ALT的水平,改善临床症状.
文摘Bacillus subtilis TA208 was selected as the test strain to optimize the fermentation medium and con- ditions of guanosine producing by single-factor experiments in shake flask. Under the optimum conditions, the productivity of guanosine was 27.34g/L in 5L auto-fermentor.
